Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

82.98EUR
2:37pm BST
Change (% chg)

€2.20 (+2.72%)
Prev Close
€80.78
Open
€82.00
Day's High
€83.58
Day's Low
€81.61
Volume
2,877,100
Avg. Vol
3,345,857
52-wk High
€118.04
52-wk Low
€75.50

Latest Key Developments (Source: Significant Developments)

Bayer: Leo Pharma Buys Bayer's Prescription Dermatology Unit
Tuesday, 31 Jul 2018 

July 31 (Reuters) - BAYER AG ::LEO PHARMA TO EXPAND LEAD IN MEDICAL DERMATOLOGY WITH ACQUISITION OF BAYER'S PRESCRIPTION DERMATOLOGY UNIT.LEO PHARMA WILL ACQUIRE GLOBAL PRODUCT RIGHTS, EXCEPT FOR AFGHANISTAN AND PAKISTAN.LEO PHARMA WILL TAKE OVER THE SALES AND MARKETING ORGANIZATIONS IN 14 COUNTRIES, AS WELL AS A FACTORY IN SEGRATE, ITALY.PORTFOLIO INCLUDES BRANDED TOPICAL PRESCRIPTION TREATMENTS FOR ACNE, FUNGAL SKIN INFECTIONS AND ROSACEA, AND RANGE OF TOPICAL STEROIDS.ACQUISITION SEEN TO CLOSE IN TWO STEPS: DURING 2018 FOR US , AND DURING THE SECOND HALF OF 2019 FOR ALL OTHER MARKETS.PORTFOLIO TO BE ACQUIRED HAS ANNUAL TURNOVER IN 2017 OF MORE THAN 280 MILLION EUROS.  Full Article

Bayer Receives Positive CHMP Opinion For Rivaroxaban For Patients With Coronary Or Peripheral Artery Disease
Friday, 27 Jul 2018 

July 27 (Reuters) - Bayer AG ::RECEIVES POSITIVE CHMP OPINION FOR RIVAROXABAN FOR PATIENTS WITH CORONARY OR PERIPHERAL ARTERY DISEASE.  Full Article

Bayer Reaffirms Safety Profile Of Essure
Friday, 27 Jul 2018 

July 26 (Reuters) - :BAYER REAFFIRMS SAFETY PROFILE OF ESSURE.NO RELIABLE SCIENTIFIC EVIDENCE TO SUGGEST THAT ANY NEW SAFETY CONCERNS EXIST WITH ESSURE.  Full Article

FDA Provides Statement On Bayer's Voluntary Recall Of Essure Permanent Birth Control Device
Friday, 20 Jul 2018 

July 20 (Reuters) - U.S. Food & Drug Administration::U.S. FDA SAYS NOTIFIED BY BAYER THAT THE ESSURE PERMANENT BIRTH CONTROL DEVICE WILL NO LONGER BE SOLD OR DISTRIBUTED AFTER DEC 31.U.S. FDA SAYS EXPECTS BAYER TO MEET ITS POSTMARKET OBLIGATIONS CONCERNING THE ESSURE PERMANENT BIRTH CONTROL DEVICE.U.S. FDA SAYS WILL CONTINUE TO MONITOR ADVERSE EVENTS REPORTED TO FDA'S DATABASE & OTHER DATA SOURCES REGARDING ESSURE PERMANENT BIRTH CONTROL DEVICE.U.S. FDA SAYS RESTRICTION ON SALE AND DISTRIBUTION OF ESSURE PERMANENT BIRTH CONTROL DEVICE WILL REMAIN IN PLACE.U.S. FDA SAYS "FOR WOMEN WHO HAVE RECEIVED AN ESSURE IMPLANT, THE POSTMARKET SAFETY OF ESSURE WILL CONTINUE TO BE A TOP PRIORITY FOR THE FDA".  Full Article

Bayer To Voluntarily Discontinue U.S. Sales Of Essure At End Of 2018
Friday, 20 Jul 2018 

July 20 (Reuters) - Bayer AG ::BAYER SAYS TO VOLUNTARILY DISCONTINUE U.S. SALES OF ESSURE SYSTEM FOR PERMANENT BIRTH CONTROL AFTER DECEMBER 31.BAYER - DECISION TO DISCONTINUE U.S. SALES OF ESSURE BASED ON DECLINING U.S. SALES, CONCLUSION THAT ESSURE BUSINESS "NO LONGER SUSTAINABLE".BAYER SAYS HAS INFORMED U.S. FDA OF CO'S DECISION TO DISCONTINUE U.S. SALES OF ESSURE.BAYER SAYS "THE SAFETY AND EFFICACY OF ESSURE HAVE NOT CHANGED".  Full Article

SA's Competition Tribunal Conditionally Approves BASF SE Acquisition Of Divestment Business Of Bayer AG
Wednesday, 18 Jul 2018 

July 18 (Reuters) - SA'S COMPETITION TRIBUNAL::CONDITIONALLY APPROVED MERGER ON GERMAN-BASED AGROCHEMICAL COMPANY BASF SE IS TO ACQUIRE DIVESTMENT BUSINESS OF BAYER AG.  Full Article

Endo, Bayer defeat Custopharm appeal over Aveed patents
Friday, 13 Jul 2018 

July 13 (Reuters) - Endo, bayer defeat appeal by custopharm over validity of patents related to testosterone replacement therapy aveed -- u.s. Court ruling:.  Full Article

German Chemicals Industry Says Revenues Up 5.5 Pct In H1
Thursday, 12 Jul 2018 

July 12 (Reuters) - LANXESS AG ::GERMAN CHEMICALS ASSOCIATION VCI SAYS IN H1 CHEMICALS PRODUCTION +5.0 PERCENT, REVENUES +5.5 PERCENT, PRICES +1.0 PERCENT.GERMAN CHEMICALS ASSOCIATION VCI REAFFIRMS EXPECTS 2018 PRODUCTION +3.5 PERCENT, PRICES +1 PERCENT AND SALES +4.5 PERCENT.GERMAN CHEMICALS ASSOCIATION VCI SAYS BUSINESS EXPECTATIONS IN THE SECTOR HAVE BECOME MORE SUBDUED, COMPANIES ARE LESS OPTIMISTIC THAN AT THE START OF THE YEAR.  Full Article

SA's Competition Commission Recommends Competition Tribunal On Zaad's Proposed Deal With Hygrotech
Monday, 9 Jul 2018 

July 9 (Reuters) - South Africa's Competition Commission::RECOMMENDED TO COMPETITION TRIBUNAL THAT ZAAD'S PROPOSED DEAL WITH HYGROTECH BE APPROVED WITHOUT CONDITIONS.RECOMMENDED THAT BASF SE GERMANY'S DEAL TO BUY DIVESTMENT BUSINESS OF BAYER BE APPROVED WITHOUT CONDITIONS.  Full Article

Bayer Backs Monsanto Takeover With EUR5 Bln Bond Issue
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Bayer AG ::SAYS CONCLUDES REFINANCING OF THE MONSANTO ACQUISITION BY PLACING BONDS WITH A VOLUME OF 5 BILLION EUROS.SAYS ISSUE OF FOUR TRANCHES WITH MATURITIES OF 4 TO 11½ YEARS WAS MORE THAN FOUR TIMES OVERSUBSCRIBED.  Full Article

Photo

Bayer says dicamba report not new

FRANKFURT Bayer said on Friday that a German media report this week that U.S. farmers were suing its Monsanto unit over crop damage caused by weedkiller dicamba does not represent a new development.